News

A study of patients recommended for statin therapy under ACC/AHA guidelines, but not taking any, found that 59.2% reported never being offered a statin.

A new cohort assessment shows white and African American men both have a lifetime hypertension risk of more than 80%.

Investigators recognize sustained virologic response to DAAs for hepatitis C infection as valid clinical endpoint of treatment, but question how it relates to long-term health.

Jatenzo's label will be marketed with a boxed warning stating it can cause risen blood pressure, thereby increasing heart attack, stroke, and cardiovascular death risks.

Higher exposure to air pollutants, especially NO2 and NOx, was found to be associated with greater odds of psychotic experiences in adolescents.

Investigators observed a 22% and 20% increased risk of heart failure during the 2 most severe influenza seasons.

Siponimod becomes first oral drug to treat secondary progressive MS to receive FDA approval.

Just 7 other states, and the District of Columbia, have passed such a law before. The bill's parameters are similar to that of Hawaii's, which passed its own law last year.

The best way to diagnose diabetic macular edema is using optical coherence tomography, but it is costly.

After demonstrating success of direct-acting antivirals for HCV in cancer patients, investigators call for their eligibility to participate in chemo trials.

The investigative solution improved patient metrics for itching, and could be considered for FDA submission later this year.

More than 80% of patients saw maintenance or improvement of BCVA, with a mean improvment of 7 letters or more, according to the ETDRS system.

Aimmune announced AR101 phase 3 trial reached its primary efficacy endpoint, intent to submit marketing authorization application.

The investigational anti-fibrotic immunomodulator is being investigated for respiratory, oncology, hepatology, and nephrology indications.

Though it has been shown to not be harmful to patients at risk for the opitcal condition, calcium may still play a protective role in these patients.

How care providers can improve their perspective and better their stress with some volunteer work where it's needed most.

Scientists at the Task Force for Global Health describe what is needed to eliminate HBV and HCV as public health threats.

One evaluated dose of AVP-786 significantly improved scores in patients with moderate-to-severe agitation related to Alzheimer dementia, compared to placebo.

First RCT to determine the efficacy of wearable digital intervention to improve social behavior of children with autism spectrum disorder.

Modeling showed that waiting until October to vaccinate would reduce flu cases in older adults, provided vaccination rates don’t decrease and flu season doesn’t peak early.

Investigators from Johns Hopkins examined 16 RCTs to determine efficacy of three anti-VEGF agents for patients with neovascular age-related macular degeneration.

The FDA’s response noted that the onset and duration of intravenous meloxicam would not meet prescriber expectations for an IV drug.

The FDA’s decision regarding sotagliflozin (Zynquista), an investigational treatment for type 1 diabetes, followed a split Advisory Committee vote in January.

The Apple Heart Study examined more than 400,000 patients over the course of a year, but some experts were less than thrilled with the outcomes.

A new long-term data analysis reports that about 50% of patients adhere to the critcal therapy after just 1 year, and the rate continues to drop after that.

Models indicate that a vaccine with just 30% efficacy would significantly reduce HCV transmission if provided to persons at high risk of infection from injecting drugs.

Patients who drank two cans of soda per day were 5 times more likely to have severe symptoms than those who "seldom" consumed it.

The breakthrough device is indicated to improve 6-minute walk distance for certain patients with chronic heart failure.